Life Sciences

Purdue Pharma to pay $634M, charged with felony over OxyContin

Pharma Compliance Alert, July 25, 2007

Purdue Pharma will pay $634 million to settle an investigation about OxyContin marketing, according to various media reports. The company will be charged with a felony. According to the government, the $634 million "represents approximately 90% of the profits for sales of OxyContin during the time period of the offense."

Purdue says that is accepts responsibility for past misstatements. The executives were also sentenced to three years of probation and "400 hours each of community service in drug treatment programs," reports The New York Times.

Go to Purdue's Web site for complete information about the settlement, including the U.S. government's response.